Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T14318 |
ARCC-4
|
Others; PROTACs | Others; PROTAC |
ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide and it is a low-nanomolar androgen receptor (AR) degrader based on PROTAC, with a DC50 of 5 nM. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy[1]. |